Bridging the Diagnostic Gap in Peripheral Arterial Disease (PAD): Leveraging Fatty Acid Binding Protein 3 (FABP3) for Biomarker-Guided Detection
Open Access
- 11 May 2026
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 16 (10) , 1457
Abstract
Background/Objective: Peripheral arterial disease (PAD) is a widespread but underdiagnosed manifestation of systemic atherosclerosis, associated with high morbidity and mortality. Traditional diagnostic methods such as the ankle-brachial index (ABI) have limited sensitivity in certain populations, highlighting the need for reliable blood-based biomarkers. Fatty Acid Binding Protein 3 (FABP3) has emerged as a robust biomarker with diagnostic utility in PAD. To evaluate the diagnostic performance of FABP3 when used in combination with traditional clinical risk factors for PAD in patients presenting to vascular surgery clinics. Methods: A retrospective analysis was conducted on 657 patients presenting to ambulatory vascular surgery clinics at St. Michael’s Hospital. Two logistic regression models were compared: (1) Model A: Included standard clinical risk factors (calf pain, age, smoking, diabetes, hypertension, hypercholesterolemia, coronary artery disease, and signs of chronic limb-threatening ischemia); and (2) Model B: Included the same factors as Model A, plus FABP3 levels. Diagnostic metrics including area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were assessed. Results: Among 657 patients, 423 had PAD and 234 did not. Model B (FABP3-integrated model) outperformed Model A, with a higher AUC (0.86 vs. 0.82), sensitivity (96% vs. 81%), specificity (84% vs. 67%), PPV (92% vs. 81%), NPV (94% vs. 65%), and diagnostic accuracy (93% vs. 76%). FABP3 also improved detection in asymptomatic PAD patients (84% detected vs. 0%). Conclusions: Integrating FABP3 with standard clinical risk factors significantly improves PAD diagnosis, especially in asymptomatic and borderline cases. These findings support the potential role of FABP3 in routine PAD screening, warranting further prospective studies for validation.Keywords
Funding Information
- The Bill and Vicky Blair Foundation
This publication has 30 references indexed in Scilit:
- The emerging role of fatty acid-binding protein 3 (FABP3) in cancerDrug Discovery Today, 2025
- Validating fatty acid binding protein 3 as a diagnostic and prognostic biomarker for peripheral arterial disease: a three-year prospective follow-up studyeClinicalMedicine, 2022
- Heart-type fatty acid-binding protein in cardiovascular disease: A systemic reviewClinica Chimica Acta, 2017
- Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysisThe Lancet, 2013
- Natriuretic PeptidesJACC, 2007
- Fatty acid-binding proteins as plasma markers of tissue injuryClinica Chimica Acta, 2005
- New insights into the fatty acid-binding protein (FABP) family in the small intestineMolecular and Cellular Biochemistry, 2002
- Atherosclerotic Risk Factors Are Less Intensively Treated in Patients with Peripheral Arterial Disease Than in Patients with Coronary Artery DiseaseJournal of General Internal Medicine, 1997
- Cellular fatty acid-binding proteins: Their function and physiological significanceProgress in Lipid Research, 1996
- Detection, tissue distribution and (sub)cellular localization of fatty acid-binding protein typesMolecular and Cellular Biochemistry, 1990